| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(14)60538-9 |
| P698 | PubMed publication ID | 24907224 |
| P50 | author | Sivi Ouwerkerk-Mahadevan | Q47158918 |
| Maria Beumont-Mauviel | Q47158921 | ||
| Fred Poordad | Q47412568 | ||
| Ewa Janczewska | Q59830669 | ||
| Patrick Marcellin | Q89798262 | ||
| Maria Buti | Q91265862 | ||
| P2093 | author name string | Yves Horsmans | |
| Oliver Lenz | |||
| Maria Beumont-Mauviel | |||
| Monika Peeters | |||
| Sivi Ouwerkerk-Mahadevan | |||
| Michael Manns | |||
| Jane Scott | |||
| Ronald Kalmeijer | |||
| Federico Villamil | |||
| Rekha Sinha | |||
| Guy De La Rosa | |||
| Evaldo Stanislau Affonso de Araujo | |||
| P2860 | cites work | Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial | Q43041743 |
| 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective | Q46917702 | ||
| Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 | ||
| An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 | ||
| Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus | Q26830190 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group | Q29614898 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study | Q33956796 | ||
| Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials | Q34100819 | ||
| Telaprevir for previously treated chronic HCV infection | Q34109057 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
| Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
| Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. | Q36335752 | ||
| Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice | Q37972758 | ||
| Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow | Q37972768 | ||
| Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. | Q38027573 | ||
| Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver | Q38034548 | ||
| Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis | Q38093509 | ||
| Novel therapies for hepatitis C - one pill fits all? | Q38117549 | ||
| New hepatitis C therapies: the toolbox, strategies, and challenges | Q38196150 | ||
| In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. | Q39736457 | ||
| Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. | Q39845360 | ||
| Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial | Q42211649 | ||
| Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial | Q42242013 | ||
| Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study | Q42977630 | ||
| Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
| Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients | Q42992022 | ||
| Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy | Q42992084 | ||
| P433 | issue | 9941 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| placebo | Q269829 | ||
| ribavirin | Q421862 | ||
| Hepatitis C virus | Q708693 | ||
| interferon alfa | Q6046441 | ||
| pegylated interferon | Q7160835 | ||
| simeprevir | Q7517689 | ||
| chronic hepatitis C | Q55779873 | ||
| chronic hepatitis | Q62019625 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 414-426 | |
| P577 | publication date | 2014-06-04 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial | |
| P478 | volume | 384 |
| Q47548210 | A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. |
| Q59475778 | A new paradigm evaluating cost per cure of HCV infection in the UK |
| Q42400012 | APASL consensus statements and recommendation on treatment of hepatitis C. |
| Q34987336 | Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits |
| Q38581352 | Alcoholic liver disease: Clinical and translational research |
| Q42202767 | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study |
| Q36138623 | All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality |
| Q36080110 | An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). |
| Q35100139 | An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver |
| Q28070279 | Anti-hepatitis C virus drugs and kidney |
| Q27022794 | Antiviral therapies for chronic hepatitis C virus infection with cirrhosis |
| Q38980602 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care |
| Q38547705 | Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions |
| Q38927201 | Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution |
| Q37056536 | Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial |
| Q38403350 | Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation |
| Q26773585 | Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q33440436 | Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. |
| Q41148230 | Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection |
| Q38544516 | Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. |
| Q33629561 | Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1 |
| Q36238515 | Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany |
| Q35088460 | Cost-effectiveness of screening for hepatitis C in Canada |
| Q38295798 | Current and future HCV therapy: do we still need other anti-HCV drugs? |
| Q26828972 | Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6 |
| Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
| Q38545043 | Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis |
| Q36724391 | Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 |
| Q40583906 | Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection |
| Q40638362 | Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin |
| Q36327795 | Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients |
| Q41127462 | Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir |
| Q38515906 | Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace |
| Q36531731 | Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus |
| Q38826176 | Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights |
| Q59349760 | Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review |
| Q57389418 | Direct-acting antivirals for chronic hepatitis C |
| Q34557595 | Direct-acting antivirals for chronic hepatitis C. |
| Q39010715 | Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? |
| Q28550311 | Drug Pricing Evolution in Hepatitis C |
| Q28084266 | Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir |
| Q38846558 | Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective? |
| Q50280201 | Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply |
| Q50280206 | Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C? |
| Q36505470 | Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection |
| Q41160646 | Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure |
| Q48219473 | Effectiveness research in the evolving HCV landscape |
| Q34451707 | Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre |
| Q34451681 | Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a |
| Q30620900 | Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. |
| Q26771458 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis |
| Q36240269 | Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response |
| Q36277394 | Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection |
| Q40291443 | Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study |
| Q28085718 | Enhancing our understanding of current therapies for hepatitis C virus (HCV) |
| Q59357400 | Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms |
| Q58603882 | Era of direct acting anti-viral agents for the treatment of hepatitis C |
| Q59357943 | Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection |
| Q36031127 | Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment |
| Q41473188 | Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. |
| Q57490314 | Expert opinion on the management of hepatitis C infection in Kuwait |
| Q90136084 | Exploring the hepatitis C virus genome using single molecule real-time sequencing |
| Q38302103 | Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism |
| Q40619693 | Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study |
| Q38974653 | Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis |
| Q64986987 | Genotypic resistance testing of HCV - is there a clinical need? |
| Q37598142 | Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis. |
| Q39491908 | HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing |
| Q57168365 | HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies |
| Q41172135 | HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials |
| Q30301355 | Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. |
| Q28084654 | Hepatitis C |
| Q26799924 | Hepatitis C cirrhosis: New perspectives for diagnosis and treatment |
| Q41758808 | Hepatitis C in African Americans |
| Q26798469 | Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? |
| Q35783876 | Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens |
| Q30378509 | Hepatitis C treatment: where are we now? |
| Q38533619 | Hepatitis C virus drug resistance-associated substitutions: State of the art summary |
| Q38887954 | Hepatitis C virus resistance to the new direct-acting antivirals |
| Q35501190 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade |
| Q38295807 | How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals |
| Q38477511 | IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors |
| Q37423627 | IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study |
| Q45323933 | Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives |
| Q35985401 | Impact of hepatitis C virus eradication on hepatocellular carcinogenesis |
| Q40845674 | Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy |
| Q40988716 | In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants. |
| Q41595435 | In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir |
| Q41722679 | Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. |
| Q59354172 | Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era |
| Q26746563 | Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection |
| Q43100552 | Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals |
| Q92608196 | Is the conquest of Hepatitis C imminent? |
| Q35947900 | Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q38793356 | Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection |
| Q40399465 | Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients |
| Q38432047 | Management of HCV in cirrhosis-a rapidly evolving landscape |
| Q26781741 | Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review |
| Q34932338 | Management of hepatitis C in patients with chronic kidney disease. |
| Q26773321 | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals |
| Q41461491 | Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant |
| Q41147723 | Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. |
| Q41007229 | Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection |
| Q36167257 | Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. |
| Q90086733 | New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials |
| Q26773271 | New approaches in the treatment of hepatitis C |
| Q38664453 | New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir |
| Q39016874 | New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). |
| Q26795407 | New treatment strategies for hepatitis C infection |
| Q45324359 | Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India |
| Q38295819 | Optimal management of patients with chronic hepatitis C and comorbidities. |
| Q38470584 | Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals |
| Q47561313 | Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection |
| Q38295802 | Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. |
| Q55017914 | Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. |
| Q41528360 | Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse |
| Q41738697 | Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C. |
| Q40085476 | Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B. |
| Q50269699 | Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity? |
| Q40671964 | Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin. |
| Q35237179 | Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy |
| Q35790397 | Predictive factors associated with hepatitis C antiviral therapy response |
| Q36488315 | Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin |
| Q40651570 | Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience |
| Q26798477 | Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications |
| Q42213830 | QUEST for a cure for hepatitis C virus: the end is in sight |
| Q33424900 | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). |
| Q40771120 | Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. |
| Q33629092 | Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study |
| Q45324716 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results |
| Q26750476 | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| Q36575497 | Recent advances in management of the HIV/HCV coinfected patient |
| Q26752433 | Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease |
| Q53836297 | Recommendations on hepatitis C screening for adults. |
| Q41145466 | Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir |
| Q47121490 | Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. |
| Q38703524 | Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy |
| Q38355069 | Revolution in hepatitis C antiviral therapy |
| Q40481366 | Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. |
| Q37216507 | SASLT guidelines: Update in treatment of Hepatitis C virus infection |
| Q26745769 | Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C |
| Q40579236 | Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis |
| Q35491398 | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? |
| Q26773306 | Simeprevir |
| Q42210312 | Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study |
| Q41752261 | Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study |
| Q41610311 | Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUES |
| Q40035445 | Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience |
| Q40353248 | Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease |
| Q38570745 | Simeprevir and sofosbuvir for treatment of hepatitis C infection |
| Q38247985 | Simeprevir for the treatment of hepatitis C virus infection |
| Q40896916 | Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience |
| Q40829783 | Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea |
| Q37631758 | Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2) |
| Q42202756 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study |
| Q41613250 | Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial |
| Q36391682 | Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study |
| Q36834349 | Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients |
| Q41680620 | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies |
| Q26769709 | Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison |
| Q33853210 | Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus |
| Q38307580 | Simeprevir: a review of its use in patients with chronic hepatitis C virus infection |
| Q37421505 | Sofosbuvir and Simeprevir Combination Therapy for HCV Genotype 1 Infection: Results of a Single-Center VA Experience |
| Q40584810 | Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation |
| Q41137675 | Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. |
| Q39609174 | Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life |
| Q38954096 | Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence |
| Q28079102 | State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization |
| Q42164795 | Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q34522481 | Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis |
| Q36951685 | TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors |
| Q26777716 | The New Era of Interferon-Free Treatment of Chronic Hepatitis C |
| Q40681112 | The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin |
| Q28086947 | The new era of hepatitis C virus therapy |
| Q28070260 | Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis |
| Q38599378 | Treatment discontinuation with peg-interferon: what to consider |
| Q38581478 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. |
| Q40893681 | Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens |
| Q41087896 | Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin |
| Q38352572 | Treatment of chronic hepatitis C in patients with HIV/HCV coinfection |
| Q26740219 | Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance |
| Q38460386 | Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy |
| Q41624184 | Treatment of hepatitis C: what is known? |
| Q35880497 | Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors |
| Q45031507 | Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849. |
| Q92354601 | Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations |
| Q41360324 | Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage |
Search more.